Use of nitrogen-containing saturated heterocyclic compounds

Nitrogen-containing saturated heterocyclic compounds, particularly in the form of pharmaceutically acceptable salts, provide an effective treatment for chronic kidney disease by improving renal function and blood pressure, addressing the lack of suitable therapeutic options with minimal side effects.

JP7579967B2Active Publication Date: 2024-11-08SHANGHAI PHARMACEUTICALS HOLDING CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2023515103
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-09-04
Filing Date
2021-09-03
Publication Date
2024-11-08
Estimated Expiration
2041-09-03

AI Technical Summary

Technical Problem

There is a lack of effective therapeutic drugs for chronic kidney disease (CKD) with minimal toxic side effects.

Method used

The use of a nitrogen-containing saturated heterocyclic compound or its pharmaceutically acceptable salts, such as malate, tartrate, hydrochloride, or naphthalene disulfonate, in the manufacture of medicaments for treating and preventing CKD, particularly in conditions like nephropathy with hypertension and abnormal glucose metabolism, chronic heart failure with chronic renal failure, or chronic kidney disease with abnormal glucose metabolism.

Benefits of technology

The nitrogen-containing saturated heterocyclic compounds demonstrate significant improvement in renal function and blood pressure regulation, showing efficacy in reducing proteinuria and glomerular filtration rate, with no adverse events observed in preclinical studies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579967000039
    Figure 0007579967000039
  • Figure 0007579967000040
    Figure 0007579967000040
  • Figure 0007579967000001
    Figure 0007579967000001
Patent Text Reader

Abstract

The present invention provides use of a nitrogen-containing saturated heterocyclic compound. Specifically, the present invention provides use of a nitrogen-containing saturated heterocyclic compound represented by the following formula I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment and / or prevention of chronic kidney disease. [Formula 1] JPEG2023539779000040.jpg56159
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the use of a nitrogen-containing saturated heterocyclic compound or a pharma- ceutically acceptable salt thereof in the manufacture of a medicament for the treatment and / or prevention of chronic kidney disease. [Background technology]

[0002] Chronic kidney disease (CKD) is characterized by high prevalence, low awareness, poor prognosis, and high medical costs, and is the third most serious health hazard after cardiovascular disease, diabetes, and malignant tumors. In recent years, the prevalence of CKD has been increasing year by year, with the global prevalence in the general population reaching 14.3%, and in China, the prevalence of CKD in the population aged 18 years and over reaching 10.8% as a result of cross-sectional epidemiological studies. Chronic kidney disease (CKD) is a progressive disease, and if treatment is not administered in time, the condition will worsen. As a result, if chronic kidney disease patients progress to renal failure, they may have difficulty surviving unless they undergo dialysis or kidney transplantation. Currently, there are no particularly effective drugs for chronic kidney disease, so it is of great clinical value to actively search for drugs that are effective in treating chronic kidney disease and have few toxic side effects.

[0003] CN103562191B discloses a nitrogen-containing saturated heterocyclic compound of the following structural formula or a pharma- ceutical acceptable salt thereof, which exhibits renin inhibitory activity and can be used for the treatment of hypertension. [ka]

[0004] Here, R 1 represents a cycloalkyl group, etc., and R 22 represents an optionally substituted aryl group or the like, R represents a lower alkyl group or the like, T represents a carbonyl group, Z represents -O- or the like, R 3 , R 4 , R 5 and R 6 are the same or different and represent hydrogen atoms, etc.

[0005] CN106928218A discloses novel pharma- ceutical usable salts of morpholine derivatives (nitrogen-containing saturated heterocycles), including their malate, tartrate, hydrochloride, acetate and naphthalenediphosphonate salts, in which the tartrate salt has three crystalline salt forms, namely, A crystal, B crystal and dihydrate, the malate, hydrochloride and acetate each have one crystalline salt form, and the naphthalenediphosphonate salt is amorphous. Compared with the known free bases of morpholine derivatives, the salts of morpholine derivatives have better crystal forms and one or more improved properties, such as significantly improved water solubility, photostability and thermal stability. The above-mentioned salts of morpholine derivatives, or their crystal forms, can be used for the treatment and / or prevention of hypertension. Summary of the Invention

[0006] The problem to be solved by the present invention is to provide use of a nitrogen-containing saturated heterocyclic compound or a pharma- ceutical acceptable salt thereof in the manufacture of a medicament for the treatment and / or prevention of chronic kidney disease, in response to the lack of a medicament in the prior art that is particularly effective for the treatment of chronic kidney disease.

[0007] The entire contents of patent CN103562191B and patent application CN106928218A mentioned in the background art are incorporated herein by reference.

[0008] In one embodiment of the present invention, there is provided the use of a nitrogen-containing saturated heterocyclic compound represented by formula I below, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and / or prevention of chronic kidney disease. [ka]

[0009] In a further embodiment of the invention, the pharma- ceutically acceptable salt is a hydrochloride, sulfate, phosphate, hydrobromide, ethanoate, fumarate, oxalate, citrate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, maleate, malate, tartrate, acetate or naphthalene disulfonate.

[0010] In a further embodiment of the invention, said pharma- ceutically acceptable salt is a malate, tartrate, hydrochloride, acetate or naphthalenedisulfonate.

[0011] In one embodiment of the invention, the pharma- ceutically acceptable salt is a malate salt of the compound of formula I, which is formed in a 1:1 molar ratio of the compound of formula I having the following structural formula and malic acid: [ka]

[0012] In one embodiment of the present invention, the malic acid is a crystalline form and its X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 7.767°±0.2°, 13.897°±0.2°, 14.775°±0.2°, 17.098°±0.2°, 18.999°±0.2°, 20.153±0.2°, 20.960°±0.2°, 21.423°±0.2°, 26.348°±0.2°, and 27.892°±0.2°. In particular, the powder X-ray diffraction pattern of the malic acid crystalline form further has characteristic peaks at 2θ of 5.598°±0.2°, 7.357°±0.2°, 10.395°±0.2°, 11.108°±0.2°, 16.037°±0.2°, 16.523°±0.2°, 19.410°±0.2°, 22.645°±0.2°, 26.630°±0.2°, 26.891°±0.2°, 27.380°±0.2°, 31.056°±0.2°, 33.306°±0.2°, 33.775°±0.2°, and 39.231°±0.2°. In particular, the malate crystalline form of the compound of formula I has an X-ray powder diffraction pattern as shown in FIG.

[0013] In one embodiment of the present invention, the chronic kidney disease includes nephropathy complicated with hypertension, nephropathy complicated with hypertension and impaired glucose metabolism, chronic heart failure complicated with chronic renal failure, or chronic kidney disease complicated with impaired glucose metabolism.

[0014] In one embodiment of the invention, said chronic kidney disease refers to chronic kidney disease stages G1, G2, G3a, G3b, G4, preferably stages G2, G3a or G3b.

[0015] In one embodiment of the present invention, the hypertension in the hypertensive nephropathy is grade 1 hypertension, grade 2 hypertension or grade 3 hypertension, preferably grade 1 hypertension or grade 2 hypertension.

[0016] In one embodiment of the invention, the dosage form of the medicament includes tablets, capsules, intravenous injections, inhalants, nebulizers, lyophilized formulations, patches, gels, sprays, or suppositories, preferably tablets.

[0017] In one embodiment of the invention, the medicament is in a unit dose.

[0018] In one embodiment of the present invention, the unit dose of the drug contains 25 mg to 200 mg, for example 25 mg, 50 mg, 100 mg, 150 mg, or 200 mg, of the nitrogen-containing saturated heterocyclic compound represented by the above formula I or a pharma- ceutically acceptable salt thereof.

[0019] The National Kidney Foundation's (NKF) Kidney Disease Prognosis Quality Initiative (KDOQI) Working Group developed standards for the definition and staging of CKD in 2002.

[0020] Chronic kidney disease is defined as an abnormality in renal structure or function that lasts for more than three months. The diagnostic criteria for chronic kidney disease are the presence of any of the indicators in Table 1 below for more than three months. [Table 1]

[0021] Stages of chronic kidney disease: Chronic kidney disease is classified into five stages based on glomerular filtration rate (GFR), as shown in Table 2 below. [Table 2]

[0022] Hypertension was defined as a systolic blood pressure (SBP) ≥ 140 mmHg (1 mmHg = 0.133 kPa) and / or a diastolic blood pressure (DBP) ≥ 90 mmHg on three separate office measurements on different days without the use of antihypertensive medication.

[0023] SBP ≥ 140mmHg and DBP < 90mmHg are considered simple systolic hypertension. Patients with a history of hypertension and currently taking antihypertensive drugs should be diagnosed with hypertension even if their blood pressure is less than 140 / 90mmHg.

[0024] Hypertension is further classified into levels 1, 2, and 3 depending on the degree of increase in blood pressure. The classification and definition of blood pressure levels are as shown in Table 3 below. [Table 3]

[0025] Heart failure is defined as a complex clinical syndrome in which ventricular filling or ejection is impaired as a result of structural or functional abnormalities of the heart. Its main clinical symptoms are dyspnea and weakness (limited activity tolerance) and fluid retention (pulmonary congestion and peripheral edema).

[0026] Heart failure is classified into three types based on left ventricular ejection fraction (LVEF): heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and heart failure with mid-range ejection fraction (HFmrEF). These types are defined as shown in Table 4 below. [Table 4]

[0027] Glucose metabolism disorders include prediabetes and diabetes.

[0028] Prediabetes refers to a state in which blood sugar levels exceed the normal range but do not reach the diagnostic criteria for diabetes, that is, a state intermediate between a normal person and a diabetic patient.

[0029] Diabetes mellitus is a common group of metabolic disorders characterized by hyperglycemia, diabetes mellitus, impaired glucose tolerance, and impaired insulin secretion.

[0030] The positive progressive effect of the present invention is that, by continuously administering a nitrogen-containing saturated heterocyclic compound salt to rhesus monkeys (middle-aged / elderly) suffering from chronic renal failure complicated with chronic heart failure for 8 weeks, it has been proven that the nitrogen-containing saturated heterocyclic compound or a pharma- ceutical acceptable salt thereof provided by the present invention is effective in preventing or treating chronic kidney disease, including nephropathy complicated with hypertension, nephropathy complicated with hypertension and glucose metabolism disorder, chronic heart failure complicated with chronic renal failure, or chronic kidney disease complicated with glucose metabolism disorder. In addition, the nitrogen-containing saturated heterocyclic compound or a pharma-ceutical acceptable salt thereof provided by the present invention has a good safety profile, and no adverse events associated with administration were observed. [Brief description of the drawings]

[0031] [Figure 1] FIG. 1 is an XRPD pattern of the malate salt of compound of formula I used in an embodiment of the present invention. [Diagram 2] 2 is the concentration-time profile of the compound of formula I in monkeys after intravenous (iv) and oral (po) administration in Example 3, where monkeys were administered a dose of 1 mg / kg intravenously and doses of 1, 3 and 9 mg / kg orally. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0032] The present invention will be further described below with reference to the embodiments, but the present invention is not limited to the embodiments described herein. In the following embodiments, the test methods for which no specific conditions are given are selected according to conventional methods and conditions or according to the instruction manual.

[0033] The malate salt of compound of formula I used in the following examples was prepared according to the preparation method described in Example 1 of patent application disclosure CN106928218A, and the structure was confirmed. Valsartan was purchased commercially. Rhesus monkeys used were purchased from Sichuan Premi Xingzhi Biotechnology Company Limited (Premi Primate Research Centre). [Table 5]

[0034] Example 1: Efficacy and safety evaluation test of the malate salt of compound of formula I administered continuously for 8 weeks to rhesus monkeys (middle-aged / elderly) suffering from chronic renal failure complicated with chronic heart failure

[0035] 1. Research Objective

[0036] The improvement of renal function by continuous administration of the malate salt of formula I compound for 8 weeks, and the effect of delaying or improving the onset of renal function, dose, potency, and risk of CVD events are evaluated, and a basis is provided for the dose design, patient inclusion criteria, and safety of clinical trials. Primary therapeutic efficacy endpoint (ENDPOINT): 1. Improvement of renal function: glomerular filtration rate (eGFR) creat-cys , cystatin C (CysC), creatinine, and UACR, 2. Improvement of cardiac function: Changes in cardiac structure and systolic and diastolic functions before and after administration were analyzed by echocardiography, 3. Safety indicators: blood pressure, blood potassium, and indicators related to glucose and lipid metabolism.

[0037] 2. Test System

[0038] 2.1 Rhesus monkeys with spontaneous chronic renal failure

[0039] Species: Macaque macaque (rhesus monkey)

[0040] Grade: Normal grade. Passed pre-examination quarantine including medical examination, two tuberculosis tests, parasite test, Salmonella, Hercobacterium and B virus tests.

[0041] Animal Identification: Stainless steel number plate with Arabic numerals on neck ring, tattoo on chest.

[0042] Provided by:Yaan Premi Biotechnology Co.

[0043] Manufacturing permit number: SCXK(Chuan)2019-027.

[0044] Veterinary certificate numbers 0016710, 0016944, 0016966.

[0045] 2.2 Selection criteria

[0046] There were 23 males and females, aged 14-24 years (corresponding to adults aged 40-70 years), with body weights ranging from 8.45-14.93 kg for males and 6.43 kg for females.

[0047] Chronic glucose or lipid metabolism disorders for 3 years or more; glucose metabolism disorders were defined as fasting plasma glucose (FPG) > 4.8mmol / l vs. 4.1±0.3mmol / l in age-matched controls.

[0048] CKD-EPI assessment: G3a-G3b, glomerular filtration rate eGFR: 30-59 ml / min / 1.73m 2 or moderately increased proteinuria (A2-A3): urinary albumin-to-creatinine ratio (UACR) of 15 mg / g to 350 mg / g (4-6 hour urine collection) vs. 3±2 mg / g in age-matched controls.

[0049] normotensive, grade 1 or grade 2 hypertension (consistent with clinical patient criteria).

[0050] HFrEF: LVEF 30-49% (normal value: 50-70% Simpson biplane method) or HFpEF (moderate or severe impairment): Ea<8 or E / Ea>10 (based on clinical diagnostic criteria).

[0051] 2.3 Exclusion criteria 1) Chronic liver disease (including known active hepatitis) and / or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times the upper limit of normal (ULN) on screening.

[0052] 2) Exclusion criteria for dyslipidemia: TC >7 mmol / l; TG >3.5 mmol / l.

[0053] 3) Any other medical history that may affect the evaluation of the efficacy of this drug.

[0054] Table 5 below shows the underlying etiology and characteristics of chronic DKD renal failure in rhesus monkeys at baseline for each subject treatment group. [Table 6] JPEG0007579967000010.jpg85159JPEG0007579967000011.jpg205159

[0055] 3. Study Design

[0056] 3.1 Grouping and Dosing Design

[0057] The study included animals in three stages. Phase I included two groups: three animals receiving 5 mg / kg of the malate salt of Formula I (#257, #4721, #287) and two animals receiving placebo (#1029, #4713). Phase II included three animals receiving 5 mg / kg of the malate salt of Formula I (#144, #5073, #6651), three animals receiving valsartan (#2091, #4861, #6645), and two animals receiving placebo (#6653, #231). Phase III included five animals receiving 2 mg / kg of the malate salt of Formula I (#4829, #6501, #287, #4721, #2091) and five animals receiving 1 mg / kg of the malate salt of Compound I (#1567, #4861, #5453, #6653, #5073).

[0058] Of these, two horses (#287 and #4721) in Phase I stopped drug administration for approximately nine months, and four horses (#5073, #2091, #4861, #6653) in Phase II stopped drug administration for approximately five months and entered the baseline period of Phase III (baseline period was one month).

[0059] For details, see Table 6 below. [Table 7]

[0060] 3.2 Drug Administration Information

[0061] Route of administration: Oral administration

[0062] Dosing frequency: The malate salt of compound of formula I was administered once daily, whereas the valsartan group was administered once daily during weeks 1-2 and twice daily during weeks 3-8 of the dosing period.

[0063] Calculation of dosage: The dosage for the following week was calculated from the body weight at each weighing.

[0064] Administration time: Administered between 08:00 and 09:00.

[0065] 3.3 Main effect indicators

[0066] Glomerular filtration rate (eGFR) creat-cys Creatinine (Cr-P), blood urea nitrogen (BUN), and cystatin (CysC) were measured, and eGFR was calculated. The tests were performed once before administration and once every 2 weeks after administration.

[0067] eGFR male =135 × min(Cr / 0.9,1) -0.207 ×max(Cr / 0.9,1) -0.601 ×min(CysC / 0.8,1) -0.375 ×max(CysC / 0.8,1) -0.711 ×0.995 Age×3

[0068] eGFRfemale=135 ×min(Cr / 0.7,1) -0.284 ×max(Cr / 0.7,1) -0.601 ×min(CysC / 0.8,1) -0.375 ×max(CysC / 0.8,1) -0.711 ×0.995 Age×3 ×0.969

[0069] UACR: Urine was collected for 4 hours and 6 hours, and urinary microalbumin (MALB) and urinary creatinine (Cr-U) were measured to calculate the UACR value. This was done once before administration and once at the end of administration. UACR=MALB / Cr-U.

[0070] Blood pressure: After anesthesia, blood pressure, including systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MBP), and heart rate (HR) were measured once before dosing and once each at 4 and 8 weeks after dosing.

[0071] Cardiac GE Doppler Ultrasound: Historical cardiac ultrasounds were performed once within 1 year (selected animals), once before dosing (within D-30 days of the baseline period), and once every 8 weeks after dosing.

[0072] 3.4 Secondary efficacy measures

[0073] Blood potassium was tested twice before treatment and every 2 weeks during treatment.

[0074] Regarding glucose and lipid metabolism and liver function: FPG, FRA, LDL-c, HDL-c, TG, TC, NT-proBNP, ALT, AST, TBIL, etc. were measured twice before administration and once each at 4 and 8 weeks during the administration period.

[0075] Other biochemical parameters and hematological tests were performed once before and once after administration of the drug.

[0076] Body weight: checked once before dosing and once every week during the dosing period.

[0077] After dosing, food intake and behavior were monitored for 24 hours each day.

[0078] 3.5 Test Methods and Equipment

[0079] Test method: See Tables 7 and 8 below.

[0080] Hematology testing equipment: Siemens ADVIA 2120i Hematolagy Systems.

[0081] Blood biochemistry and urine testing equipment: Roche cobas6000 analyzer series C501 module was used, and NT-proBNP was tested using an ELISA kit. [Table 8] [Table 9]

[0082] 3.6 Cardiac Doppler Ultrasound

[0083] Anesthesia: 15 mg / kg of ketamine hydrochloride was used for intramuscular anesthesia, and supplementary anesthesia was administered at 1 / 2 the initial dose depending on the anesthetized state of the animal at the discretion of the veterinarian.

[0084] Detection method: The animals were placed in a left lateral recumbent position, and images were acquired using a 6S-RS probe (frequency 2.7 to 8.0 MHz).

[0085] Analysis: Images were stored and repeated for three consecutive cardiac cycles using the EchoPAC Software analysis workstation to measure systolic and diastolic function.

[0086] Examination indicators and ultrasound diagnostic methods: See Table 9 below.

[0087] Examination equipment: GE Vivid S5 color Doppler ultrasound machine.

[0088] 3.7 Blood Pressure Test

[0089] Testing method: The animals were anesthetized by intramuscular injection of 15 mg / kg ketamine hydrochloride, placed in supine position after anesthesia, the hair on the left upper arm was shaved cleanly, and a cuff of appropriate size was tied according to the standard. The blood oxygen probe was clamped between the animal's finger or toe (except the left hand), the red light receiving surface was placed on the ventral side of the finger, and the blood pressure of the animal was measured three times in succession using the automatic mode, with a 1-minute interval between each measurement. If the difference between DBP, SBP and MBP in the blood pressure for more than three times was small (the difference between the highest and lowest values ​​was less than 15 mmHg), the measurement was terminated.

[0090] Laboratory indices included systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MBP), and heart rate (HR).

[0091] Testing equipment: GE B40i electrophysiology monitor. [Table 10] JPEG0007579967000016.jpg21159

[0092] 3.8 Clinical Observations

[0093] Observation frequency: once per day

[0094] Observation method: Observe in a separate cage.

[0095] Observations: changes in injection sites, skin, hair, eyes, ears, nose, mouth, chest, abdomen, urogenital area and limbs, as well as breathing, movement, urination, defecation and behavior.

[0096] 3.9 Measuring Food Intake

[0097] Feeding method: Feeding was done once each at 8:00-9:00, 10:00, 14:00, and 16:00. It was confirmed that there was food in the feeding box, and the animals were allowed to eat ad libitum. The remaining food was removed the next day between 07:40 and 08:00.

[0098] Feeding amount: Approximately 250-500 g / head / day. Food was secured in a feeding box for 24 hours during the test, and the animals were allowed to eat the food ad libitum.

[0099] Feed intake measurement: Feed was estimated semi-quantitatively and the amount of feed given, fed and left in the box was recorded daily: Feed intake = Feed given - Feed left - Feed left in the box.

[0100] 3.10 Weight measurement

[0101] Weighing time: Before feeding on the day.

[0102] Measurement method: Animals were fasted for 14–16 h, weighed, placed conscious in a transfer cage, and weighed on a large animal scale.

[0103] Detection equipment: METTLER TOLEDO electronic balance.

[0104] 4.0 Study Termination Criteria

[0105] A serious adverse event occurred.

[0106] b. A serious infection occurs.

[0107] 5. Results and Analysis

[0108] 5.1 Impact on UACR

[0109] CKD rhesus monkeys showing moderate to severe increase in proteinuria with baseline urinary albumin / creatinine ratio (UACR) ≥ 15 mg / g - 350 mg / g (4-6 hour urine collection) were selected, and the results of analyzing the change in albumin / creatinine ratio at baseline and 8 weeks (W8) of administration in each group are shown in Table 10 below.

[0110] Placebo group (n=4): The average increase rate of UACR at the end of the test period W8 from the baseline was 30.64±34.50%, and the proteinuric UACR of the four animals fluctuated stably within a certain range, with no rapid progression being observed.

[0111] Valsartan group (n=3, moderate to severe increase in proteinuria was also included in the analysis): Two animals (#2091, #4861) administered W8 showed a 40-70% decrease in UACR compared to baseline, and both showed benefit. One animal had a baseline UACR of 15mg / g, and after administration of W8, the UACR was 20.4%, which was not a significant difference, but the benefit was recognized. Due to the small number of selected animals, no statistical difference was observed compared to the placebo group.

[0112] Formula I compound malate (5 mg / kg once daily (qd)) group (n=6, including 4 / 6 animals with moderate to severe proteinuria): The average reduction rate of UACR after W8 administration was 46.87 ± 36.93% compared to baseline, which showed a significant reduction compared to the placebo group (p<0.05). Here, there were three animals in which UACR was reduced by 60-70% compared to baseline by W8 administration, all of which showed efficacy, but one animal showed no efficacy.

[0113] Formula I compound malate (2 mg / kg qd) group (n=5, including 3 / 5 animals with moderate to severe proteinuria): The mean reduction in UACR in W8 after administration was 66.00±17.42% compared to baseline, which was significantly reduced compared to the placebo group (p<0.01). When W8 was administered, 3 animals showed a reduction in UACR of approximately 50% to 80% compared to baseline, indicating efficacy.

[0114] Formula I compound malate (1 mg / kg qd) group (n=5, 2 / 5 animals with moderately severely increased proteinuria included in statistics): UACR at W8 after administration was reduced by 39% compared to baseline in 1 animal, and 1 animal showed no efficacy.

[0115] In conclusion, administration of the compound of formula I, malic acid, at 2-5 mg / kg qd for 8 weeks significantly improved proteinuria (UACR). [Table 11] JPEG0007579967000018.jpg138159

[0116] 5.2 Glomerular filtration rate (eGFR) creat-cys Impact on

[0117] The effect on eGFR in each group is shown in Tables 11 and 12 below. eGFRcreat-cys in each group: 30-59 ml / min / 1.73m 2 The changes in glomerular filtration rate from baseline to W8 after treatment were analyzed.

[0118] Placebo group (n=4): Compared to baseline, 4 animals had a lower glomerular filtration rate (eGFR) creat-cys fluctuated steadily within a certain range and did not show any rapid progression.

[0119] Valsartan group (n=3): Glomerular filtration rate (eGFR) after W8 valsartan administration compared to baseline creat-cys The average was 6±2ml / min / 1.73m 2 The change in glomerular function was significantly increased compared to the placebo group (p<0.01), and glomerular deterioration was significantly improved, demonstrating time-dependent efficacy.

[0120] Malate salt of compound of formula I (5 mg / kg qd) group (n=6): W8 glomerular filtration rate (eGFR) after administration compared to baseline creat-cys The average increase was 6±6 ml / min / 1.73m 2 , which showed a significant increase compared to the change in the placebo group (p<0.05), and demonstrated efficacy in a time-dependent manner.

[0121] Malate salt of compound of formula I (2 mg / kg qd) group (n=5): W8 glomerular filtration rate (eGFR) after administration compared to baseline creat-cys The average increase was 3±3 ml / min / 1.73m 2 , which showed a significant increase compared with the change in the placebo group (p < 0.05).

[0122] Malate salt of compound of formula I (1 mg / kg qd) group (n=5): W8 glomerular filtration rate (eGFR) after administration compared to baseline creat-cys The average increase was 3±4 ml / min / 1.73m 2 , which did not show a significant increase compared with the change in the placebo group.

[0123] In conclusion, the administration of the compound of formula I, malic acid, at 2-5 mg / kg qd for 8 weeks significantly increased glomerular filtration rate (eGFR) creat-cys was significantly improved. [Table 12] [Table 13]

[0124] 5.3 Effects on CysC, Cr-P and BUN

[0125] The effects on CysC, Cr-P, and BUN in each group after administration are shown in Tables 13 to 15 below. [Table 14] [Table 15] [Table 16]

[0126] 5.4 Effects on blood pressure

[0127] The effect of drug administration on blood pressure in each treatment group is shown in Table 16. Since blood pressure testing in primates requires anesthesia, it was necessary to control heart rate variability at various time periods in order to perform statistical analysis.

[0128] Placebo group (n=4, 2 / 4 hypertension): Compared to baseline, 4 animals had stable fluctuations in blood pressure within range.

[0129] Valsartan group (n=3, 1 / 3 hypertension): Compared to baseline, the mean reductions in SBP and DBP at W8 after administration were 14±4mmHg and 7±0mmHg, respectively, which were highly significant compared to the changes in the placebo group (p<0.01).

[0130] Formula I compound malate (5 mg / kg qd) group (n=6, 4 / 6 cases with hypertension): Compared to baseline, the mean reductions in SBP and DBP at W8 after administration were 21±8 mmHg and 10±7 mmHg, respectively, which were highly significant reductions compared to the changes in the placebo group (p<0.01), indicating time-dependent efficacy.

[0131] Formula I compound malate (2 mg / kg qd) group (n=5, 2 / 5 cases with hypertension): Compared to baseline, the mean reductions in SBP and DBP at W8 after administration were 19±9 mmHg and 9±8 mmHg, respectively, which were highly significant reductions compared to the changes in the placebo group (p<0.01), indicating time-dependent efficacy.

[0132] Formula I compound malate (1 mg / kg qd) group (n=5): Compared to baseline, the mean reductions in SBP and DBP at W8 after administration were 11±4 mmHg and 5±4 mmHg, respectively, which were significantly reduced compared to the changes in the placebo group (p<0.05).

[0133] In conclusion, all of the malate salts of formula I compound administered at 1-5 mg / kg qd for 8 weeks were effective in lowering blood pressure. [Table 17]

[0134] 5.5 Effects on cardiac function

[0135] The effect of each group on echocardiographic indices is shown in Table 17.

[0136] No significant adverse effects on cardiac systolic or diastolic function were observed in any of the doses of the malate salt of formula I compound, the valsartan group, or the placebo group.

[0137] In addition, two rhesus monkeys in the 5 mg / kg group of the malate salt of formula I compound showed reduced ejection fraction (SD) (#5073, #287), and LVEF% increased compared to baseline at 8 weeks after administration. However, data from subsequent cohorts is needed to support whether this product can be effective in treating chronic heart failure. [Table 18]

[0138] 5.6 Effect of cardiac dysfunction on blood biomarkers

[0139] 5.6.1 Effect on NT-proBNP

[0140] The effect of the malate salt of the compound of formula I on NT-proBNP is shown in Table 18.

[0141] In animals in each treatment group, no significant changes were observed in NT-proBNP levels after 8 weeks of treatment compared with the baseline period. [Table 19]

[0142] 5.6.2 K + Effect on

[0143] K + The effect of the malate salt of the compound of Formula I on is shown in Table 19.

[0144] Serum K after 8 weeks of treatment in animals of each treatment group + No significant changes were observed compared with baseline. [Table 20]

[0145] 5.7 Safety tolerance testing

[0146] During treatment, no treatment-related adverse events were observed in the group receiving the compound of formula I in malic acid form, and no significant changes were observed in liver function, renal function, food intake, body weight, or hematological parameters.

[0147] 6. Summary

[0148] Administration of 2-5 mg / kg qd of the malate salt of compound I for 8 weeks significantly improved proteinuria (UACR) and glomerular filtration rate (eGFR). creat-cys The efficacy of this treatment was similar to that of the valsartan group.

[0149] The malate salt of formula I compound was administered at doses of 1-5 mg / kg qd for 8 weeks and had antihypertensive effects without any risk of hyperkalemia under the conditions of this study.

[0150] Example 2: Preclinical Safety Evaluation of Formula I Compounds

[0151] 1. Materials and Methods

[0152] 1.1. Test substances

[0153] The compound of formula I was prepared and the structure was confirmed according to the method of CN103562191B. The solvent was 0.5% sodium carboxymethylcellulose (CMC-Na). The compound of formula I was stored at room temperature, protected from light and moisture. For safety testing in cynomolgus monkeys, the test substance was suspended at the relevant concentration in 0.5% CMC-Na. The prepared suspension was analyzed for homogeneity, concentration and 1-week stability to ensure correct administration of the reported dose. A 6-month accelerated stability test of the active pharmaceutical ingredient (API) was performed.

[0154] 1.2. Animal husbandry

[0155] Healthy male and female cynomolgus monkeys aged 3-4 years were provided by Hainan New Source Biotechnology Ltd (Hainan, China). The weight range at the start of administration was 3.2-5.8 kg for males and 2.5-3.7 kg for females. A 36-day habituation period was set before the study. Food and water were provided ad libitum once a day in the morning.

[0156] This nonclinical study was conducted in accordance with the guidelines of the China Food and Drug Administration (CFDA). The study was conducted in an international Association for Assessment and Accreditation of Laboratory Animal Care (AAA LAC)-approved facility, and animals were maintained in accordance with the Guide for the Care and Use of Laboratory Animals (Nussberger et al., 2008).

[0157] 1.3. Dosage and treatment schedule

[0158] Cynomolgus monkeys (5 / sex / group) were selected using a weight-based computerized randomization procedure and administered the compound of formula I intranasally at dose levels of 0 (control), 20, 100, and 450 mg / kg / day in a volume of 5 ml / kg. Individual doses were adjusted weekly according to the animal's weight. For all groups, 2 / 3 of the animals were randomly selected and euthanized on day 28. The remaining animals were euthanized 28 days after drug cessation.

[0159] 1.4. Clinical Observations

[0160] Once the quarantine period began, animals were assessed daily for mortality and clinical signs, and each animal was observed at least twice daily for behavior, response to drug administration, and onset of disease.

[0161] Observations included, but were not limited to, changes in skin and hair, eyes and mucous membranes, respiratory, circulatory, autonomic and central nervous systems, and behavioral patterns. Rectal temperatures were measured before the first dose (twice), 1 and 24 hours after the first dose, and before and 1 and 24 hours after the dose on day 26, respectively. Body weights were measured weekly. Food consumption of the monkeys was estimated daily. Ophthalmoscopy of the monkeys was performed using a portable slit lamp (YZ2) and a direct vision ophthalmoscope (GFJY-01B).

[0162] 1.5. Laboratory measurements

[0163] In the monkey study, the following parameters were measured during the isolation period (twice on days 01 and 02), 14, 28, and 56, as shown in Table 20 below. (1) Blood and coagulation indices were performed using a Bayer ADVIA2120 (Germany) and a Sysmex CA-1500 (Japan). (2) Serum biochemistry tests were evaluated using a HITACHI 7080 autoanalyzer (Japan) and an Easylyte PLUS electrolyte analyzer (MEDICA, USA). (3) 24-hour urine was collected from each animal through a tray under each cage. Urine analysis was performed using a Uritest-300 (China). (4) 24-hour pooled feces were collected from each monkey through a tray under each cage. Fecal occult blood detection was performed. (5) Cardiac troponin (TropI, non-GLP) tests were performed using the ACCESS 2 chemiluminescent immunoassay. [Table 21] JPEG0007579967000029.jpg34159

[0164] 1.6. Conventional ECG Analysis

[0165] Routine electrocardiogram analysis was performed at each scheduled time (day 1 after administration, day 01 after administration, day 02 after administration, 1 hour and 24 hours after day 1 after administration, and 1 hour and 24 hours after day 56 after administration). An inductor DII (ECG-6951E, Shanghai, China) was used for the ECG system, and P waves, R waves, T waves, PR intervals, QT intervals, QRS durations, and heart rates were recorded.

[0166] 1.7. Autopsy and histopathology

[0167] Complete visual necropsies were performed on all animals at the end of the exposure phase (day 28) and recovery phase (day 56). The following selected organs were excised, weighed, and assessed for absolute weight and percentage of final body weight or brain weight: brain, heart, kidneys, liver, spleen, thymus, testes, epididymis, uterus, ovaries, adrenal glands, and thyroid gland (including parathyroid gland). The following tissues were preserved in 10% neutral formalin: brain, pituitary gland, thyroid gland (including parathyroid gland), trachea, heart, pancreas, spleen, adrenal gland, prostate, ovary, uterus (including cervix and fallopian tube), vagina, testis, epididymis, seminal vesicle, esophagus, duodenum, jejunum, ileocecal tract, colon, rectum, mesenteric lymph nodes, lymph nodes, submandibular lymph nodes, aorta, eyeball, skeletal muscle, sciatic nerve, femur (including epiphysis), breast, sternum, salivary gland, spinal cord, bladder, lung (including bronchi), liver, kidney, stomach, bone marrow (sternum), thymus, gallbladder, and any tissues with obvious lesions or masses. Lung tissue was infected with fixative at the time of necropsy. All preserved tissues were embedded, sectioned, stained with hematoxylin and eosin (HE), and examined microscopically. Smears (monkey sternum) and paired embedded sternum sections were examined for bone marrow cell morphology.

[0168] 1.8. Toxicokinetics

[0169] Blood samples were collected at 0, 0.5, 1.5, 3, 5, 7, and 24 hours on the first and 26th days after administration. Approximately 1.0 mL of blood was collected from the vein each time and diluted with EDTA-K. 2Blood samples were collected in anticoagulant tubes. Blood samples were placed on ice and centrifuged (3500 rpm, 5 min) at 4°C to obtain plasma samples, which were frozen at about -80°C until analysis. The toxicokinetic assay of Formula I compound was carried out at Shanghai Institute of Medical Sciences, Chinese Academy of Sciences.

[0170] 1.9. Statistical analysis

[0171] For each sex, body weight, rectal temperature, electrocardiogram, organ weight, hematological parameters, and serum biochemical data were analyzed using the statistical software SAS 9.3. First, homogeneity of variance was analyzed with Levene's test. If P > 0.05, one-way ANOVA was used. If P < 0.05, Kruskal-Wallis test was used. If the resulting p-value of ANOVA was < 0.05, Dunnett t-test was used to compare each group. If the resulting p-value of Kruskal-Wallis test was < 0.05, Dunnett t-test was performed after rank transformation of the data.

[0172] 2.Results

[0173] 2.1. Clinical Observations

[0174] Body weight gain was slightly reduced in the high-dose group compared with the control group (females, 2.7±0.4 vs. 3.2±0.2; males, 4.1±0.5 vs. 4.6±0.5), but this difference was not statistically significant.

[0175] Early treatment-related mortality occurred in one high-dose female on day 23, with clinical signs including hypokinesia, hunched posture, hypothermia, diarrhea, mild intestinal blistering, and thymus atrophy. No other animals showed obvious signs of treatment-related clinical toxicity.

[0176] 2.2. Hematology / Coagulation

[0177] Increases in NEUT% and decreases in LYMPH% were observed in females at all doses and in high-dose males, as well as increases in Fbg in mid- and high-dose animals and APTT in high-dose females (Table 21). [Table 22]

[0178] 2.3. Serum biochemistry

[0179] Serum chemistry parameters CPK, BUN, and CREA were significantly increased in male and female cynomolgus monkeys at the high dose, especially in the animals that died early on day 23 (data on day 14, BUN: 34.99, CREA: 526). CHOL was significantly lower in males at the high dose. Serum Na concentration was slightly decreased in the high dose group, but was statistically significant on day 26. Other statistically significant occurrences were isolated events considered to be of no toxicological importance (Table 22). [Table 23]

[0180] 2.4.Urine Testing

[0181] No significant changes were reported in any of the urinalysis parameters examined in either male or female monkeys.

[0182] 2.5. ECG parameters

[0183] One mid-dose female had a prolongation of the QTc interval at 1 hour on day 26 (animal #303, 296 ms). Sinus arrhythmia with prolongation of the QRS interval was observed in one high-dose male at 1 hour on day 26 (animal #411, 60 ms). High-dose females also had a prolongation of the QRS interval at 1 hour on days 1 and 26 (Table 23). [Table 24] JPEG0007579967000033.jpg147159

[0184] 2.6. Autopsy

[0185] 2.6.1. Gross pathology and organ weights

[0186] Macroscopic findings in the monkeys were not considered to be related to test substance administration, except for mild intestinal blistering and thymus atrophy in the predecessor monkey. Relative liver and kidney weights were higher, relative thymus weights were lower, and absolute and relative uterus weights were lower in the high-dose group (Table 24). [Table 25] JPEG0007579967000035.jpg115159

[0187] 2.7. Toxicokinetics

[0188] Proportional increase in systemic exposure (plasma AUC of the drug substance and major metabolites of the compound) 0-24h and C max The increase in the α-amyloid β ...

[0189] Example 3: Non-clinical pharmacokinetic studies

[0190] 1. Materials and Methods

[0191] 1.1. Materials

[0192] According to the method of CN103562191B, the compound of formula I was prepared and the structure was confirmed.

[0193] 1.2. Animals

[0194] Cynomolgus monkeys (3 / sex / group: body weight 3-5 kg, age 5-6 years) were obtained from Suzhou Xishan Zhongke Laboratory Animals (Shanghai, China). The animals were acclimated for 7 days prior to the study. The monkeys were individually caged and further placed in an animal room with controlled temperature (18-26°C) and humidity (50±20%), air flow rate of 10, and fresh air exchanged every hour. The photoperiod was 12 hours on and 12 hours off, and the monkeys were given food and water once a day in the morning. All animal studies were performed in accordance with the Guide for the Care and Use of Animals prepared by the AMMS Animal Welfare Committee.

[0195] 2. Intravenous and Oral Administration of Formula I Compounds

[0196] Compounds of formula I were administered intravenously or orally to overnight fasted cynomolgus monkeys. Doses were 1 mg / kg (intravenous), 1 mg / kg, 3 mg / kg, and 9 mg / kg (orally). Blood samples (0.2 mL at each time point) were collected from the vein at 0, 5, and 15 min, respectively, at 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 h after dosing. Immediately after collection, all blood samples were centrifuged at 10,000×g for 5 min, and plasma was stored at −75 ± 10° C. until analysis. Plasma samples were prepared by protein precipitation. Concentrations of compounds of formula I in plasma were measured by validated liquid chromatography-tandem mass spectrometry.

[0197] Area under the plasma concentration time curve (AUC), maximum plasma concentration (C max ), C max Time to reach (T max ), half-life (T 1 / 2 ), total plasma clearance (CL), mean residence time (MRT), steady-state volume of distribution (V ssPharmacokinetic parameters such as CV, CV, and CV were calculated using WinNonlin v1.3 (Pharsight, Mountain View, CA, USA) in a non-atrial-ventricular analysis. For anisotropic growth models, animal pharmacokinetic data were simulated using a two-compartment model and the Kinetica 5.1 package (v.3.0; InnaPhase, Philadelphia, PA, USA).

[0198] 3.Results

[0199] Plasma pharmacokinetics and bioavailability

[0200] Pharmacokinetic data for intravenous and oral administration in cynomolgus monkeys are shown in Table 25 and Figure 2. After intravenous administration, the drug concentration declined biexponentially, with a clearance of 1.96 L / h / kg and a volume of distribution of 1.86 L / kg in monkeys. After oral administration, the compound of formula I increased in C over 1.0-1.30 hours. max Then, T 1 / 2 The drug disappeared from plasma within 2.73-5.99 hours after administration. AUC 0-24h Calculations of oral bioavailability of the compound of formula I in monkeys ranged from 3.3 to 11.3%, suggesting the involvement of efflux transport proteins. [Table 26]

[0201] Clearance after CL iv, V ss Volume of distribution at steady state after i.v., MRT Mean residence time, T 1 / 2 Half-life, C max maximum plasma concentration, T max C max Time to reach, AUC tot Total area under the plasma concentration-time curve, CL / F Clearance after oral administration, V ss / F steady state volume of distribution after oral administration, F oral absolute bioavailability, iv intravenous administration, po oral administration

Claims

1. Use of a nitrogen-containing saturated heterocyclic compound represented by the following formula I, or a pharma- ceutical acceptable salt thereof, in the manufacture of a medicament for the treatment and / or prevention of chronic renal failure complicated by chronic heart failure. 【Chemistry 1】

2. 2. The use according to claim 1, wherein the pharma- ceutically acceptable salt is a hydrochloride, sulfate, phosphate, hydrobromide, ethanoate, fumarate, oxalate, citrate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, maleate, malate, tartrate, or naphthalenedisulfonate.

3. 3. The use of claim 1 or 2, wherein the pharma- ceutically acceptable salt is a malate salt of a compound formed in a 1:1 molar ratio of the compound of formula I and malic acid, the compound having the following structural formula: 【Chemistry 2】

4. 4. The use according to claim 3, wherein the malic acid is crystalline and its X-ray powder diffraction pattern has characteristic peaks at 2θ angles of 7.767°±0.2°, 13.897°±0.2°, 14.775°±0.2°, 17.098°±0.2°, 18.999°±0.2°, 20.153±0.2°, 20.960°±0.2°, 21.423°±0.2°, 26.348°±0.2°, and 27.892°±0.2°.

5. The use described in claim 4, wherein the powder X-ray diffraction pattern of the malic acid crystalline body further has characteristic peaks at 2θ of 5.598°±0.2°, 7.357°±0.2°, 10.395°±0.2°, 11.108°±0.2°, 16.037°±0.2°, 16.523°±0.2°, 19.410°±0.2°, 22.645°±0.2°, 26.630°±0.2°, 26.891°±0.2°, 27.380°±0.2°, 31.056°±0.2°, 33.306°±0.2°, 33.775°±0.2°, and 39.231°±0.2°.

6. 3. The use according to claim 1 or 2, wherein the pharmaceutical dosage form comprises a tablet, a capsule, an intravenous injection, an inhalant, a nebulizer, a lyophilized agent, a patch, a gel, a spray, or a suppository.

7. 3. The use according to claim 1 or 2, wherein the medicament is in a unit dose.

8. The use according to claim 7, wherein the unit dose of the medicament contains the nitrogen-containing saturated heterocyclic compound represented by the above formula I or a pharma- ceutically acceptable salt thereof in the range of 25 mg to 200 mg.

9. The use according to claim 7, wherein the unit dose of the medicament contains 25 mg, 50 mg, 100 mg, 150 mg, or 200 mg of the nitrogen-containing saturated heterocyclic compound of formula I or a pharma- ceutically acceptable salt thereof.

Citation Information

Patent Citations

  • Galenus preparation for aliskiren

    JP2010501524A

  • Galenic preparations containing aliskiren and methods for preparing them by melt extrusion granulation.

    JP2012503665A

  • Pharmaceutical composition

    JP2014074024A

  • Salts of morpholine derivatives, crystalline forms thereof, methods for producing the same, pharmaceutical compositions containing the same and uses thereof

    JP2019500385A

  • Nitrogen-containing saturated heterocyclic compound

    WO2012124775A1